Edgewise Therapeutics, Inc. (EWTX) stock
EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$42.04−1.64 (-3.75%)
Close on Nov 17, 2026Market cap $4.57BP/E –Yield –
Edgewise Therapeutics cash
Cash and short-term investments held at the end of each period.
Edgewise Therapeutics's cash was $72.32M at Jun 30, 2026. For fiscal 2025 it was $61.15M, up 46.8% from the year before. The highest annual figure on record is $104.92M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.15M | +46.8% |
| FY2024 | Dec 31, 2024 | $41.67M | -51.6% |
| FY2023 | Dec 31, 2023 | $86.10M | +291.5% |
| FY2022 | Dec 31, 2022 | $21.99M | +41.3% |
| FY2021 | Dec 31, 2021 | $15.57M | -85.2% |
| FY2020 | Dec 31, 2020 | $104.92M | +343.6% |
| FY2019 | Dec 31, 2019 | $23.65M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $72.32M | +66.6% |
| Q1 FY2026 | Mar 31, 2026 | $33.21M | -33.5% |
| Q4 FY2025 | Dec 31, 2025 | $61.15M | +46.8% |
| Q3 FY2025 | Sep 30, 2025 | $46.00M | +2.7% |
| Q2 FY2025 | Jun 30, 2025 | $43.40M | -0.2% |
| Q1 FY2025 | Mar 31, 2025 | $49.92M | +65.0% |
| Q4 FY2024 | Dec 31, 2024 | $41.67M | -51.6% |
| Q3 FY2024 | Sep 30, 2024 | $44.81M | +36.0% |
| Q2 FY2024 | Jun 30, 2024 | $43.49M | +36.7% |
| Q1 FY2024 | Mar 31, 2024 | $30.26M | -37.3% |
| Q4 FY2023 | Dec 31, 2023 | $86.10M | +291.5% |
| Q3 FY2023 | Sep 30, 2023 | $32.96M | -70.0% |
| Q2 FY2023 | Jun 30, 2023 | $31.81M | +73.4% |
| Q1 FY2023 | Mar 31, 2023 | $48.23M | +40.0% |
| Q4 FY2022 | Dec 31, 2022 | $21.99M | +41.3% |
| Q3 FY2022 | Sep 30, 2022 | $109.75M | +938.2% |
| Q2 FY2022 | Jun 30, 2022 | $18.34M | -63.6% |
| Q1 FY2022 | Mar 31, 2022 | $34.45M | -84.4% |
| Q4 FY2021 | Dec 31, 2021 | $15.57M | -85.2% |
| Q3 FY2021 | Sep 30, 2021 | $10.57M | -72.7% |
| Q2 FY2021 | Jun 30, 2021 | $50.40M | +198.8% |
| Q1 FY2021 | Mar 31, 2021 | $221.04M | +957.3% |
| Q4 FY2020 | Dec 31, 2020 | $104.92M | +343.6% |
| Q3 FY2020 | Sep 30, 2020 | $38.73M | – |
| Q2 FY2020 | Jun 30, 2020 | $16.87M | – |
| Q1 FY2020 | Mar 31, 2020 | $20.91M | – |
| Q4 FY2019 | Dec 31, 2019 | $23.65M | – |
See a number that looks wrong?